Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Usefulness of an RNA extraction-free test for the multiplexed detection of ALK, ROS1, and RET Gene Fusions in Real Life FFPE Specimens of Non-Small Cell Lung Cancers.
Damiola F, Alberti L, Mansuet-Lupo A, Damotte D, Hofman V, Tixier L, Penault-Llorca F, Rouquette I, Vignaud JM, Cazes A, Forest F, Begueret H, Gibault L, Badoual C, Cayre A, Taranchon-Clermont E, Duc A, Mc Leer A, Lantuejoul S. Damiola F, et al. Among authors: tixier l. Expert Rev Mol Diagn. 2023 Jul-Dec;23(12):1283-1291. doi: 10.1080/14737159.2023.2277367. Epub 2023 Dec 15. Expert Rev Mol Diagn. 2023. PMID: 37906110
[Strategy for molecular testing in pulmonary carcinoma].
Penault-Llorca F, Tixier L, Perrot L, Cayre A. Penault-Llorca F, et al. Among authors: tixier l. Ann Pathol. 2016 Jan;36(1):73-9. doi: 10.1016/j.annpat.2015.11.005. Epub 2016 Jan 8. Ann Pathol. 2016. PMID: 26778816 Review. French.
Compliance to genomic test recommendations to guide adjuvant chemotherapy decision-making in the case of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, in real-life settings.
Hequet D, Hajjaji N, Charafe-Jauffret E, Boucrauta A, Dalenc F, Nicolai V, Lopez J, Tredan O, Deluche E, Fermeaux V, Tixier L, Cayre A, Menet E, Lerebours F, Rouzier R. Hequet D, et al. Among authors: tixier l. Cancer Med. 2023 Aug;12(16):16889-16895. doi: 10.1002/cam4.6315. Epub 2023 Jul 6. Cancer Med. 2023. PMID: 37409516 Free PMC article.
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Ginzac A, Molnar I, Durando X, Motte Rouge T, Petit T, D'hondt V, Campone M, Bonichon-Lamichhane N, Venat Bouvet L, Levy C, Augereau P, Pistilli B, Arsene O, Jouannaud C, Nguyen S, Cayre A, Tixier L, Mahier Ait Oukhatar C, Nabholtz JM, Penault-Llorca F, Mouret-Reynier MA. Ginzac A, et al. Among authors: tixier l. Breast Cancer Res Treat. 2024 Jun;205(2):267-279. doi: 10.1007/s10549-024-07285-y. Epub 2024 Mar 7. Breast Cancer Res Treat. 2024. PMID: 38453781 Free PMC article. Clinical Trial.
[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France].
Franchet C, Djerroudi L, Maran-Gonzalez A, Abramovici O, Antoine M, Becette V, Berghian A, Blanc-Fournier C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Duprez-Paumier R, Fleury C, Ghnassia JP, Haudebourg J, Leroux A, MacGrogan G, Mathieu MC, Michenet P, Penault-Llorca F, Poulet B, Robin YM, Roger P, Russ E, Tixier L, Treilleux I, Valent A, Verriele V, Vincent-Salomon A, Arnould L, Lacroix-Triki M; Pour le GEFPICS. Franchet C, et al. Among authors: tixier l. Ann Pathol. 2021 Nov;41(6):507-520. doi: 10.1016/j.annpat.2021.07.014. Epub 2021 Aug 12. Ann Pathol. 2021. PMID: 34393014 French.
30 results